Annalisa Chiarenza, Dr

Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Italy

NA

Poster(s):

• 1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling

• 2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?